Anavex Life Sciences (AVXL) Share-based Compensation Growth (5y) (2015 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Anavex Life Sciences | 266.20 Mn | 134.45 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.34% |
| Sep 30, 2025 | 61.46% |
| Jun 30, 2025 | 28.15% |
| Mar 31, 2025 | -3.15% |
| Dec 31, 2024 | 10.20% |
| Sep 30, 2024 | 41.19% |
| Jun 30, 2024 | 43.08% |
| Mar 31, 2024 | 6.97% |
| Dec 31, 2023 | 2.03% |
| Sep 30, 2023 | 16.62% |
| Jun 30, 2023 | 18.17% |
| Mar 31, 2023 | 26.50% |
| Dec 31, 2022 | 36.65% |
| Sep 30, 2022 | 40.24% |
| Jun 30, 2022 | 28.02% |
| Mar 31, 2022 | 35.58% |
| Dec 31, 2021 | 34.46% |
| Sep 30, 2021 | -3.79% |
| Jun 30, 2021 | 58.37% |
| Mar 31, 2021 | 52.66% |
| Dec 31, 2020 | 2.60% |
| Sep 30, 2020 | -13.56% |
| Jun 30, 2020 | 156.43% |
| Dec 31, 2019 | 141.60% |
| Sep 30, 2019 | 14.50% |
| Jun 30, 2019 | 164.19% |
| Sep 30, 2018 | 8.27% |
| Jun 30, 2017 | 63.65% |
| Mar 31, 2017 | 64.62% |
| Dec 31, 2016 | 48.47% |
| Sep 30, 2016 | 71.15% |
| Jun 30, 2016 | 7.66% |
| Mar 31, 2016 | -19.74% |
| Dec 31, 2015 | 34.49% |
| Sep 30, 2015 | 56.47% |